// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























914 Abstracts

A Clinical-Molecular Signature of Progression of Idiopathic Pulmonary Fibrosis (IPF)

J. Oldham - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

A Multivariable Protein-Inclusive Predictor of Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis: Data from the IPF-PRO Registry

J. L. Todd - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Impact of Telomere Length on Circulating T Cell Receptor Repertoire, Phenotype, and Function After Lung Transplantation for Idiopathic Pulmonary Fibrosis

M. E. Snyder - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

lonomycin

Skeletal Muscle Size and Fat Infiltration of the Limb Muscles in Idiopathic Pulmonary Fibrosis

D. Rozenberg - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

ABT-263 (Navitoclax) Induces Fibroblast Apoptosis and Reduces Fibrosis in Two Mouse Models of Progressive Fibrotic Interstitial Lung Disease

J. Cooley - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Idiopathic pulmonary fibrosis

Navitoclax

Changes in Radiological Features in Patients with Progressive Fibrosing ILDs Treated with Nintedanib: A Sub-Study of The INBUILD Trial

S. L. Walsh - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Idiopathic pulmonary fibrosis

Nintedanib

Elucidation the Role of Macrophage Ageing in Idiopathic Pulmonary Fibrosis

M. El-Hajjar - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Bleomycin

Outcomes of Acute Exacerbation in Idiopathic Pulmonary Fibrosis and Connective Tissue Disease-Related Interstitial Lung Disease Treated with Systemic Corticosteroids Alone vs Systemic Corticosteroids with Immunosuppressive Therapy: A Systematic Review and Meta-Analysis

S. Duangkham - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Lung Cancer in Patients with Idiopathic Pulmonary Fibrosis: A Retrospective Multicenter Study in Europe

T. Karampitsakos - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Idiopathic pulmonary fibrosis

N/A

Analysis of Forced Vital Capacity (FVC) Trajectories in Idiopathic Pulmonary Fibrosis (IPF) Identifies Four Distinct Clusters of Disease Behaviour

H. Fainberg - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Post-Transplant Survival in Patients with Idiopathic Pulmonary Fibrosis with Moderate and Severe Pulmonary Hypertension

B. H. Lashari - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Idiopathic pulmonary fibrosis

N/A

Characteristics of Lung Transplant Recipients with Idiopathic Pulmonary Fibrosis and Moderate or Severe Secondary Pulmonary Hypertension, and Determinants of Post-Transplant Survival

B. H. Lashari - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Idiopathic pulmonary fibrosis

N/A

A Rare Case of Concurrent Post-Transplant Lymphoproliferative Disease and Pseudomonas Pneumonia

M. Arif - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Idiopathic pulmonary fibrosis

Rituximab

Antisynthetase Syndrome Presenting as Isolated Interstitial Lung Disease in a 90-Year-Old Female

F. Abbas - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Idiopathic pulmonary fibrosis

Mycophenolate mofetil

Pm2.5 Impacts on Telomere Length in Patients with Idiopathic Pulmonary Fibrosis

G. C. Goobie - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Altered Pathways of Hypoxia in Lung Fibroblasts and Their Relationship with the Development of Idiopathic Pulmonary Fibrosis

A. Aquino-Galvez - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Nontuberculous Mycobacterial Infection Presenting as a Classic Right Upper Lobe Cavitary Lesion in a Lung Transplant Recipient

M. T. Olson - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Idiopathic pulmonary fibrosis

clarithromycin

Lung Function Trajectories in Patients with Idiopathic Pulmonary Fibrosis: Data from the IPF-PRO Registry

M. Neely - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Sildenafil Added to Pirfenidone in Patients with Advanced Idiopathic Pulmonary Fibrosis (IPF) and Risk of Pulmonary Hypertension (PH): Impact on Health-Related Quality of Life

W. A. Wuyts - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Idiopathic pulmonary fibrosis

Pirfenidone

Long-Term Outcomes in Patients with Idiopathic Pulmonary Fibrosis (IPF) Split by Surgical Lung Biopsy (SLBx) Status: A Post-Hoc Analysis from the Pooled CAPACITY Studies

S. Weigt - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Pirfenidone

Copyright © 2026. QuantiNova All rights reserved